Munich to Witness Establishment of Biotechnology Center Starting from 2026
Munich is set to become a beacon for biotech innovation, with the establishment of BioLabs|TUM, an innovation center for biotechnology. This state-of-the-art facility, launched through a partnership between TUM Venture Labs, BioLabs, and Eli Lilly and Company, aims to accelerate the development of groundbreaking therapies [1][4].
Optimal Conditions for Biotech Startups
BioLabs|TUM offers fully equipped laboratories and office space for 15 to 20 young companies, providing an immediate operational environment without the need for startups to build out lab infrastructure themselves. The center is strategically located in the city center of Munich, making it easily accessible for both startups and industry partners [2].
A Unique Co-working Environment
The innovation center is part of the global BioLabs network, which offers a unique co-working environment combining furnished office space with fully supported labs. This fosters community and collaboration among early-stage biotech companies, helping to nurture the growth of innovative ideas [3].
Expert Support and Integrated Networks
Selected startups at BioLabs|TUM will have access to the expertise of Lilly's scientific experts, as well as strategic consulting. Furthermore, they will benefit from connections to BioLabs’ affiliated venture fund, Mission BioCapital, and numerous industry partnerships, providing crucial access to capital and industry networks [5].
Strengthening Munich's Biotech Scene
The alliance between Lilly, BioLabs, and TUM creates a new hub in Munich's startup ecosystem. With its strong scientific community and renowned facilities, Munich is an ideal location for BioLabs|TUM. This collaboration is expected to strengthen the international visibility of Munich's biotech scene [6].
A Shared Passion for Bold Scientific Breakthroughs
Lilly shares a common passion for bold scientific breakthroughs with BioLabs|TUM. Julie Gilmore, Vice President and Global Head of Lilly Gateway Labs, supports the collaboration between Lilly and BioLabs|TUM, stating that it "offers an opportunity to support and nurture early-stage innovation in Munich" [7].
Advancing Therapeutic Development
The goal of BioLabs|TUM is to accelerate the development of groundbreaking therapies. By bringing together scientific talent, venture capital, and pharmaceutical expertise, it aims to create a fertile environment where early-stage biotech ventures can thrive, quickly translating research results into marketable applications [8].
The innovation center, BioLabs|TUM, is scheduled to launch in early 2026. With its unique offerings and strategic location, it is poised to make a meaningful contribution to the biotech industry and the development of innovative therapies that can make a difference for patients worldwide [9].
[1] TUM Venture Labs [2] BioLabs [3] Eli Lilly and Company [4] Mission BioCapital [5] BioLabs|TUM Press Release [6] Lilly Gateway Labs [7] Julie Gilmore, Vice President and Global Head of Lilly Gateway Labs [8] BioLabs|TUM Website [9] BioLabs|TUM Launch Date
- The biotech innovation center, BioLabs|TUM, launched through a partnership with TUM Venture Labs, BioLabs, and Eli Lilly and Company, is set to accelerate the development of groundbreaking therapies and therapies and treatments in Munich.
- By providing fully equipped laboratories and office space for startups, BioLabs|TUM offers an immediate operational environment, allowing young companies to focus on their research and development without the need to build out lab infrastructure themselves.
- The unique co-working environment at BioLabs|TUM, part of the global BioLabs network, fosters community and collaboration among early-stage biotech companies, supporting the growth of innovative ideas.
- Selected startups at BioLabs|TUM will have access to the expertise of Lilly's scientific experts, strategic consulting, connections to venture capital, and industry partnerships, providing crucial access to capital and industry networks.
- With its strong scientific community, renowned facilities, and strategic location, Munich's new hub, BioLabs|TUM, is expected to strengthen the international visibility of Munich's biotech scene and contribute meaningfully to the biotech industry and the development of innovative therapies.
